T
Tamar Rachmilewitz Minei
Publications - 15
Citations - 98
Tamar Rachmilewitz Minei is an academic researcher. The author has contributed to research in topics: Bevacizumab & Ovarian cancer. The author has an hindex of 3, co-authored 11 publications receiving 59 citations.
Papers
More filters
Journal ArticleDOI
A randomized controlled phase III study of VB-111 combined with bevacizumab vs bevacizumab monotherapy in patients with recurrent glioblastoma (GLOBE).
Timothy F. Cloughesy,Andrew Brenner,John de Groot,Nicholas Butowski,Leor Zach,Jian Campian,Benjamin M. Ellingson,Laurence S. Freedman,Yael C Cohen,Noa Lowenton-Spier,Tamar Rachmilewitz Minei,Shifra Fain Shmueli,Patrick Y. Wen +12 more
TL;DR: In this study, upfront concomitant administration of VB-111 and bevacizumab failed to improve outcomes in rGBM and change of treatment regimen, with the lack of Vb-111 monotherapy priming, may explain the differences from the favorable phase II results.
Journal ArticleDOI
Safety and efficacy of VB-111, an anticancer gene therapy, in patients with recurrent glioblastoma: results of a phase I/II study.
Andrew Brenner,Katherine B. Peters,James J. Vredenburgh,Felix Bokstein,Deborah T. Blumenthal,Shlomit Yust-Katz,Idit Peretz,Bernice Oberman,Laurence S. Freedman,Benjamin M. Ellingson,Timothy F. Cloughesy,Naamit Sher,Yael C Cohen,Noa Lowenton-Spier,Tamar Rachmilewitz Minei,Niva Yakov,Itzhak Mendel,Eyal Breitbart,Patrick Y. Wen +18 more
TL;DR: Patients with rGBM who were primed with VB-111 monotherapy that continued after progression with the addition of bevacizumab showed significant survival and PFS advantage, as well as specific imaging characteristics related to Vb-111 mechanism of action.
Journal ArticleDOI
Ofranergene obadenovec (VB-111) in platinum-resistant ovarian cancer; favorable response rates in a phase I/II study are associated with an immunotherapeutic effect
Rebecca C. Arend,Hannah M. Beer,Yael C Cohen,Suzanne Berlin,Michael J. Birrer,Susana M. Campos,Tamar Rachmilewitz Minei,Dror Harats,Jaclyn A. Wall,McKenzie E. Foxall,Richard T. Penson +10 more
TL;DR: Treatment with VB-111 in combination with paclitaxel was safe and well tolerated and favorable tumor responses and overall survival outcomes were associated with induction of an immunotherapeutic effect.
Journal Article
ND0612, a novel liquid formulation of levodopa/carbidopa for subcutaneous infusion in patients with Parkinson’s disease achieves stable levodopa plasma levels when administered in low and high doses (S4.002)
Nir Giladi,Yoseph Caraco,Tanya Gurevich,Ruth Djaldetti,Liat Adar,Yael C Cohen,Tamar Rachmilewitz Minei,Sheila Oren +7 more
TL;DR: Subcutaneous administration of ND0612 provides steady, therapeutic levodopa plasma concentrations that were associated with clinical improvement, and may provide an effective, non-invasive alternative for continuous levodOPA delivery.
Journal ArticleDOI
Ofranergene obadenovec (VB-111) in platinum resistant ovarian cancer: with an immunotherapeutic effect.
Yael C Cohen,Suzanne Berlin,Michael J. Birrer,Susana M. Campos,Tamar Rachmilewitz Minei,Dror Harats,Richard T. Penson +6 more
TL;DR: VB-111 is a targeted anti-cancer gene therapy with a dual mechanism: anti angiogenic/vascular disruption and induction of an anti-tumor directed immune response that incursions into the normal immune response.